Advanced Solid Tumor Clinical Trials in Philadelphia, Pennsylvania

22 studies are recruiting for advanced solid tumor in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

   This is a Phase 1/2, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic mesothelioma or other Advanced solid tumors. The study consists of two par…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pennsylvania - Abramson Cancer Center, Philadelphia, Pennsylvania

   Locations

   10 in total

   Run by

   InSilico Medicine Hong Kong Limited

   See if you can join NCT06566079 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

   This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Jefferson University Hospitals - Kimmel Cancer Center, Philadelphia, Pennsylvania

   Locations

   18 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT05898399 on ClinicalTrials.gov

4. An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

   This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894 (discontinued), and in combination with standard …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

   Locations

   101 in total

   Run by

   BeOne Medicines

   See if you can join NCT06589596 on ClinicalTrials.gov

5. Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

   ONC-783-001 is a Phase I open label, dose-escalation study for evaluating the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania

   Locations

   3 in total

   Run by

   OncoC4, Inc.

   See if you can join NCT07408258 on ClinicalTrials.gov

6. Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

   The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   #1010, University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   26 in total

   Run by

   Debiopharm International SA

   See if you can join NCT04855656 on ClinicalTrials.gov

7. A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: * What is the recommended dosing for BGB-B455? * What medical problems do participant…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

   Locations

   11 in total

   Run by

   BeOne Medicines

   See if you can join NCT06803680 on ClinicalTrials.gov

8. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

   The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   80 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04104776 on ClinicalTrials.gov

9. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

   This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Investigative Site #109, Philadelphia, Pennsylvania

   Locations

   18 in total

   Run by

   MOMA Therapeutics

   See if you can join NCT06545942 on ClinicalTrials.gov

10. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Fox Chase Cancer Center, Philadelphia, Pennsylvania

    Locations

    47 in total

    Run by

    Synthekine

    See if you can join NCT05098132 on ClinicalTrials.gov

11. A Study of PYX-201 in Advanced Solid Tumors

    The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania

    Locations

    29 in total

    Run by

    Pyxis Oncology, Inc

    See if you can join NCT05720117 on ClinicalTrials.gov

12. SNV1521 in Participants With Advanced Solid Tumors

    This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also invest…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Thomas Jefferson University, Philadelphia, Pennsylvania

    Locations

    25 in total

    Run by

    Synnovation Therapeutics, Inc.

    See if you can join NCT06220864 on ClinicalTrials.gov

13. Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

    This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841. The Phase 1 part is dose escalation with 7 dose levels of ONC-841 and the dose e…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

    Locations

    8 in total

    Run by

    OncoC4, Inc.

    See if you can join NCT06352359 on ClinicalTrials.gov

14. Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

    This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: * Dose Escalation Part: To evaluate the safety and tolerability …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sidney Kimmel Cancer Center - Thomas Jefferson, Philadelphia, Pennsylvania

    Locations

    28 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT04145622 on ClinicalTrials.gov

15. A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

    This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Abramson Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania

    Locations

    8 in total

    Run by

    Peel Therapeutics Inc

    See if you can join NCT05329103 on ClinicalTrials.gov

16. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia, Pennsylvania

    Locations

    19 in total

    Run by

    NiKang Therapeutics, Inc.

    See if you can join NCT06586957 on ClinicalTrials.gov

17. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

    Locations

    21 in total

    Run by

    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

18. JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

    This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

    Locations

    10 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT06108050 on ClinicalTrials.gov

19. FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

    This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

    Locations

    14 in total

    Run by

    Fate Therapeutics

    See if you can join NCT06241456 on ClinicalTrials.gov

20. Study of AVZO-021 in Patients With Advanced Solid Tumors

    This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sidney Kimmel Cancer Center (SKCC) at Jefferson Health, Philadelphia, Pennsylvania

    Locations

    13 in total

    Run by

    Avenzo Therapeutics, Inc.

    See if you can join NCT05867251 on ClinicalTrials.gov

21. A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

    This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and max…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Fox Chase Cancer Center, Philadelphia, Pennsylvania

    Run by

    Fox Chase Cancer Center

    See if you can join NCT04827810 on ClinicalTrials.gov

22. A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

    This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical …

    Stage

    Phase 2

    Ages

    0 to 25

    Site

    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

    Locations

    35 in total

    Run by

    Day One Biopharmaceuticals, Inc.

    See if you can join NCT04775485 on ClinicalTrials.gov